Vladimir Kadinov
Vladimir Kadinov
UMNAT "St. Marina "
Verified email at mu-varna.bg
TitleCited byYear
Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
W Park, DH Yoo, P Miranda, M Brzosko, P Wiland, S Gutierrez-Ureña, ...
Annals of the rheumatic diseases 76 (2), 346-354, 2017
1762017
A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from …
DH Yoo, A Racewicz, J Brzezicki, R Yatsyshyn, ET Arteaga, ...
Arthritis research & therapy 18 (1), 82, 2016
1272016
Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis …
W Park, DH Yoo, J Jaworski, J Brzezicki, A Gnylorybov, V Kadinov, ...
Arthritis research & therapy 18 (1), 25, 2016
1092016
Efficacy and Safety of CT-P13 (Infliximab Biosimilar) over Two Years in Patients with Ankylosing Spondylitis: Comparison Between Continuing with CT-P13 and Switching from …
W Park, P Miranda, M Brzosko, P Wiland, S Gutierrez-Ureña, H Mikazane, ...
Arthritis & Rheumatism 65 (12), 2013
472013
OP0068 A phase 3 randomised controlled trial to compare CT-P13 with infliximab in patients with active rheumatoid arthritis: 54 week results from the planetra study
DH Yoo, A Racewicz, J Brzezicki, R Yatsyshyn, ET Arteaga, ...
Annals of the Rheumatic Diseases 72 (Suppl 3), A73-A73, 2013
372013
FRI0421 A randomised, double-blind, parallel-group, phase 1 study comparing the pharmacokinetics, safety and efficacy of ct-p13 and infliximab in patients with active …
W Park, J Jaworski, J Brzezicki, A Gnylorybov, V Kadinov, IG Sariego, ...
Annals of the Rheumatic Diseases 72 (Suppl 3), A516-A517, 2013
302013
5-lipoxygenase mediates docosahexaenoyl ethanolamide and N-arachidonoyl-L-alanine-induced reactive oxygen species production and inhibition of proliferation of head and neck …
SW Park, JH Hah, SM Oh, WJ Jeong, MW Sung
BMC cancer 16 (1), 458, 2016
112016
AB0860 Impact of treatment with adalimumab on disease activity, work productivity and workday loss in patients with ankylosing spondylitis
S Bogdanova, S Dimitrov, S Hristova, T Shivacheva, V Kadinov
Annals of the Rheumatic Diseases 71 (Suppl 3), 687-687, 2013
2013
CHANGE IN BMD DURING TREATMENT WITH IBANDRONATE ADMINISTERED INTRAVENOUSLY: RESULTS DURING A PERIOD OF 2 YEARS OF OBSERVATION
S Bogdanova, S Dimitrov, S Hristova, T Shivacheva, V Kadinov
OSTEOPOROSIS INTERNATIONAL 24, S255-S255, 2013
2013
APPLICATION OF FRACTURE RISK ASSESSMENT TOOL (FRAX) TO PREDICT NEED FOR DXA SCANNING AND TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS AT RISK OF OSTEOPOROSIS
SH Hristova, SP Dimitrov, S Bogdanova, TK Shivacheva, VN Kadinov
OSTEOPOROSIS INTERNATIONAL 23, S178-S179, 2012
2012
COMPLIANCE TO OSTEOPOROSIS TREATMENT-IS THE OSTEOPOROSIS FRACTURE A REASON FOR A BETTER TREATMENT?
S Hristova, S Dimitrov, T Shivacheva, V Kadinov
OSTEOPOROSIS INTERNATIONAL 22, 279-280, 2011
2011
The system can't perform the operation now. Try again later.
Articles 1–11